Abstract
Background: Melatonin has oncostatic actions and IL-25 is active in inflammatory processes that induce apoptosis in tumor cells. Aim: The aim of this study was to evaluate melatonin and IL-25 in metastatic (CF-41) and non-metastatic (CMT-U229) canine mammary tumor cells cultured as monolayers and tridimensional structures. Materials and Methods: The cells were treated with melatonin, IL-25 and IL-17B silencing gene and performed cell viability, gene and protein expression of caspase-3 and VEGFA (Vascular endothelial growth factor A) and an apoptosis membrane protein array. Results: Treatment with 1 mM of melatonin reduced cell viability of both tumor cell lines, all treatments alone and combined significantly increased caspase-3 cleaved and proteins involved in the apoptotic pathway and reduced pro-angiogenic VEGFA, confirming the effectiveness of these potential promising treatments. Conclusion: This is the first study evaluating the potential use of these strategies in CF-41 and CMT-U229 cell lines and together encourages subsequent in vitro and in vivo studies for further exploration of clinical applications.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 1572-1584 |
| Number of pages | 13 |
| Journal | Veterinary and Comparative Oncology |
| Volume | 15 |
| Issue number | 4 |
| DOIs | |
| State | Published - Dec 1 2017 |
Fingerprint
Keywords
- angiogenesis
- apoptosis
- canine
- interleukin-25
- mammary tumour cells
- melatonin
ASJC Scopus subject areas
- veterinary(all)
Cite this
Melatonin and IL-25 modulate apoptosis and angiogenesis mediators in metastatic (CF-41) and non-metastatic (CMT-U229) canine mammary tumour cells. / Gelaleti, G. B.; Borin, Thaiz Ferraz; Maschio-Signorini, L. B.; Moschetta, M. G.; Hellmén, E.; Viloria-Petit, A. M.; Zuccari, D. A.P.C.
In: Veterinary and Comparative Oncology, Vol. 15, No. 4, 01.12.2017, p. 1572-1584.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Melatonin and IL-25 modulate apoptosis and angiogenesis mediators in metastatic (CF-41) and non-metastatic (CMT-U229) canine mammary tumour cells
AU - Gelaleti, G. B.
AU - Borin, Thaiz Ferraz
AU - Maschio-Signorini, L. B.
AU - Moschetta, M. G.
AU - Hellmén, E.
AU - Viloria-Petit, A. M.
AU - Zuccari, D. A.P.C.
PY - 2017/12/1
Y1 - 2017/12/1
N2 - Background: Melatonin has oncostatic actions and IL-25 is active in inflammatory processes that induce apoptosis in tumor cells. Aim: The aim of this study was to evaluate melatonin and IL-25 in metastatic (CF-41) and non-metastatic (CMT-U229) canine mammary tumor cells cultured as monolayers and tridimensional structures. Materials and Methods: The cells were treated with melatonin, IL-25 and IL-17B silencing gene and performed cell viability, gene and protein expression of caspase-3 and VEGFA (Vascular endothelial growth factor A) and an apoptosis membrane protein array. Results: Treatment with 1 mM of melatonin reduced cell viability of both tumor cell lines, all treatments alone and combined significantly increased caspase-3 cleaved and proteins involved in the apoptotic pathway and reduced pro-angiogenic VEGFA, confirming the effectiveness of these potential promising treatments. Conclusion: This is the first study evaluating the potential use of these strategies in CF-41 and CMT-U229 cell lines and together encourages subsequent in vitro and in vivo studies for further exploration of clinical applications.
AB - Background: Melatonin has oncostatic actions and IL-25 is active in inflammatory processes that induce apoptosis in tumor cells. Aim: The aim of this study was to evaluate melatonin and IL-25 in metastatic (CF-41) and non-metastatic (CMT-U229) canine mammary tumor cells cultured as monolayers and tridimensional structures. Materials and Methods: The cells were treated with melatonin, IL-25 and IL-17B silencing gene and performed cell viability, gene and protein expression of caspase-3 and VEGFA (Vascular endothelial growth factor A) and an apoptosis membrane protein array. Results: Treatment with 1 mM of melatonin reduced cell viability of both tumor cell lines, all treatments alone and combined significantly increased caspase-3 cleaved and proteins involved in the apoptotic pathway and reduced pro-angiogenic VEGFA, confirming the effectiveness of these potential promising treatments. Conclusion: This is the first study evaluating the potential use of these strategies in CF-41 and CMT-U229 cell lines and together encourages subsequent in vitro and in vivo studies for further exploration of clinical applications.
KW - angiogenesis
KW - apoptosis
KW - canine
KW - interleukin-25
KW - mammary tumour cells
KW - melatonin
UR - http://www.scopus.com/inward/record.url?scp=85016392441&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85016392441&partnerID=8YFLogxK
U2 - 10.1111/vco.12303
DO - 10.1111/vco.12303
M3 - Article
C2 - 28322030
AN - SCOPUS:85016392441
VL - 15
SP - 1572
EP - 1584
JO - Veterinary and Comparative Oncology
JF - Veterinary and Comparative Oncology
SN - 1476-5810
IS - 4
ER -